Company Overview of Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including hepatitis C virus (HCV), influenza virus, and norovirus. The company also develops targeted in-house chemical libraries consisting of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. It has research collaboration agreement with HitGen, Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Cocrystal P...
1860 Montreal Road
Tucker, GA 30084
Founded in 2007
Key Executives for Cocrystal Pharma, Inc.
Co-Founder, Vice Chairman and Interim Chief Executive Officer
Total Annual Compensation: $100.6K
Co-Founder and President
Total Annual Compensation: $260.8K
Compensation as of Fiscal Year 2016.
Cocrystal Pharma, Inc. Key Developments
Cocrystal Pharma, Inc., HitGen, Ltd. and InterX, Inc. Enter into Drug Discovery Collaboration
Sep 5 17
Cocrystal Pharma, Inc. announced that it has entered into a research collaboration with HitGen Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Through the collaboration, Cocrystal, HitGen and InterX scientists will apply HitGen's DNA-encoded library (DEL) technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs. The DEL technology enables a large number of compounds to be rapidly identified for specific drug targets. Cocrystal will use its industrialized crystallization and co crystallization technology to determine at near atomic resolution the structures of HitGen's selected library compounds that interact with drug targets. Finally, InterX will use its advanced proprietary software to design superior drugs from the information provided by Cocrystal and HitGen. The goal of the collaboration is to produce superior drugs rapidly, without the need for extensive time-consuming and expensive chemical synthesis and testing. A Joint Steering Committee will oversee the project and manage the program.
Cocrystal Pharma, Inc. Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection
Aug 15 17
Cocrystal Pharma, Inc. announced the successful completion and positive data from the Phase 1a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus (HCV)-infected individuals. CC-31244 is a broad-spectrum, potent NS5B non-nucleoside inhibitor (NNI) of HCV replication with a high barrier to resistance. This randomized, placebo-controlled, double-blind Phase 1a/1b study was designed to evaluate single and multiple ascending doses of CC-31244 for safety/tolerability, pharmacokinetics, and antiviral activity in HCV-infected patients. In Phase 1a, 30 healthy volunteers received single doses (20-400 mg) of CC-31244, and 12 healthy volunteers received repeated doses of CC-31244 (either 200 or 400 mg) for 7 days. In Phase 1b, 15 patients with HCV genotype-1 infection received CC-31244 for 7 days (6, 400 mg daily; 6, 600 mg daily; 3, 200 mg twice daily). Eighteen subjects received placebo during the study. There were no dose-limiting adverse events, study discontinuations due to adverse events, or serious adverse events reported. Viral load data showed that CC-31244 administered once daily (400 mg or 600 mg) or twice daily (200 mg) for 7 days had a substantial and durable antiviral effect, with an average HCV RNA viral load decline from baseline of 3 log orders by Day 4. Interestingly, the average viral load at 6 days after the last dose persisted in the range of 1.7-2.0 log orders below baseline. HCV genotype 1b cell-based replicon assays using combinations of CC-31244 with other classes of HCV drugs showed additive and synergistic effects of CC-31244, providing important information for ultra-short therapy cocktail regimen. Summary of key findings: There were no dose-limiting adverse events, study discontinuations due to adverse events, or serious adverse events reported with CC-31244. CC-31244 monotherapy for 7 days established an excellent proof-of-concept for the anti-HCV activity of CC-31244 resulting in a mean viral load reduction of 3 log orders. The slow rebound post treatment is a unique feature of CC-31244 resulting in a lingering antiviral effect of up to 2 log orders after 6 days post last dose.
Cocrystal Pharma Appoints James J. Martin as Chief Financial Officer
Jun 10 17
Cocrystal Pharma reported the appointment of James J. Martin to the position of Chief Financial Officer. Since February 23, Martin had served as Interim Chief Financial Officer of Cocrystal. From 2014 to 2016 Martin was the Chief Financial Officer of VBI Vaccines, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 20, 2017